mRNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the blueprint for functional proteins in the body and induces therapeutic effects.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

The COVID-19 pandemic exposed a stark bottleneck: vaccine production was heavily centralized. High-income countries produced roughly 80 percent of all doses, while, for instance, under one percent of ...

Nov 19 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the ...

The global mRNA therapeutics market size stood at USD 10.66 billion in 2024 and is anticipated to increase from USD 12.31 billion in 2025 to reach around USD 45.04 billion by 2034, expanding at a CAGR ...

Ongoing federal support for mRNA technology and research could make good on a longstanding presidential promise to cure cancer, according to Jeff Coller, Bloomberg Distinguished Professor of RNA ...

Here's what the United States stands to lose if the federal government broadly divests of mRNA medicines after spending decades readying the technology for prime time. Cancer treatment On a molecular ...

Hematologic malignancies encompass a group of cancers that stem from lymphohematopoietic system. These malignancies include such categories as: acute and chronic leukemias, lymphomas, multiple ...